Aflibercept plus FOLFIRI for 2nd line treatment of metastatic colorectal cancer (mCRC): Long-term safety observation from the global aflibercept safety and quality-of-life (QoL) program (ASQoP)

Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSPRIECHELMANN, R.SRIMUNINNIMIT, V.KAVAN, P.BARTOLOMEO, M. DiMAIELLO, E.CICIN, I.KROENING, H.GARCIA-ALFONSO, P.CHAU, I.FERNANDEZ-MARTOS, C.TER-OVANESOV, M.PEETERS, M.PICARD, P.BORDONARO, R.2017-05-192017-05-192016ANNALS OF ONCOLOGY, v.27, suppl.6, 20160923-7534https://observatorio.fm.usp.br/handle/OPI/19832engrestrictedAccessAflibercept plus FOLFIRI for 2nd line treatment of metastatic colorectal cancer (mCRC): Long-term safety observation from the global aflibercept safety and quality-of-life (QoL) program (ASQoP)conferenceObjectCopyright OXFORD UNIV PRESS10.1093/annonc/mdw370.100Oncology1569-8041